Highlights

  • a2 Milk received SAMR approval to transition two China-label infant milk formula registrations to a2™ branded products.
  • The approval completes the final regulatory requirement linked to the acquisition of the a2 Pokeno manufacturing facility.
  • The board is expected to meet soon with the intention of declaring a fully franked and unimputed special dividend of approximately $300 million.

The a2 Milk Company Limited (ASX:A2M) (NZX:ATM) has reached an important regulatory milestone after confirming that it has received approval from China's State Administration for Market Regulation (SAMR) to transition two China-label infant milk formula (IMF) product registrations acquired through the a2 Pokeno facility acquisition into a2™ branded products.

The announcement, released on 22 June 2026, represents a significant development in the company's long-term China strategy and comes at a time when investors continue to monitor the company's ability to expand its presence in one of the world's largest infant nutrition markets.

Shares of a2 Milk closed at AUD 6.77 on 22 June, up 0.89% for the trading session, reflecting ongoing investor attention to the company's regulatory progress and future earnings initiatives.

Understanding the SAMR Approval

China's infant formula industry remains one of the most regulated dairy categories globally. Product registrations issued by SAMR are essential for companies seeking to market and distribute infant formula products in mainland China.

For a2 Milk, the newly approved registrations were acquired as part of its purchase of the a2 Pokeno facility. The latest approval allows these registrations to be utilized under the company's own a2™ brand, creating greater flexibility in product development and commercialization.

Management described the approval as the final step required under the acquisition agreement. Importantly, the company confirmed that it no longer retains the option to unwind the acquisition, signaling that the transaction has now effectively reached full completion from a regulatory perspective.

The approval removes a key uncertainty surrounding the deployment of the registrations and provides greater visibility regarding the company's future manufacturing and market access plans in China.

Strategic Importance of the China Market

China continues to represent a major contributor to a2 Milk's infant nutrition business. Despite demographic challenges associated with declining birth rates, the market remains attractive due to demand for premium nutrition products and consumer focus on product quality, safety, and brand reputation.

The company has historically generated substantial revenue from Chinese consumers, particularly through its infant milk formula portfolio. Consequently, regulatory approvals that expand product access and enhance manufacturing capabilities can have meaningful implications for future growth opportunities.

According to Managing Director and Chief Executive Officer David Bortolussi, the SAMR approval supports several strategic objectives. These include strengthening market access, enabling product innovation, accelerating advanced nutritional manufacturing capabilities, and increasing profitability through greater vertical integration.

The ability to launch additional China-label products under the a2 brand may also improve the company's competitive positioning in a market where regulatory approvals can act as barriers to entry.

a2 Pokeno Facility and Supply Chain Transformation

The acquisition of the a2 Pokeno facility was designed to provide greater control over production and supply chain operations.

Historically, many infant nutrition companies have relied on third-party manufacturers. By expanding ownership of production assets, a2 Milk seeks to capture a larger portion of the value chain while improving operational flexibility.

Management has consistently highlighted the potential benefits of vertical integration, including enhanced product development capabilities, manufacturing efficiencies, and improved margin capture.

The latest approval strengthens the strategic rationale behind the acquisition by ensuring the associated China-label registrations can now be fully utilized under the company's branding framework.

The company also reiterated that there is no change to the timing of expected product launches or the financial benefits outlined when the acquisition was originally announced. New products are expected to enter the market later in calendar year 2026.

Special Dividend Expected to Move Forward

Another significant aspect of the announcement concerns capital management.

a2 Milk stated that, following receipt of the required regulatory approvals, the board is expected to convene with the intention of declaring a special dividend worth approximately $300 million.

The proposed payment is expected to be fully franked and unimputed, making it a noteworthy event for shareholders.

While the dividend has not yet been formally declared, the company indicated that further details regarding payment timing and associated terms will be communicated in a separate market announcement.

The anticipated distribution reflects the company's balance sheet position and follows commitments previously outlined when the Pokeno acquisition was announced.

Investors often pay close attention to special dividends because they represent a direct return of capital and can influence shareholder returns independently of ongoing operating performance.

Growth Outlook Following the Regulatory Milestone

Looking ahead, attention is likely to focus on the commercialization of the newly approved products and the broader execution of a2 Milk's China growth strategy.

The company now has greater certainty regarding access to the registrations associated with the Pokeno facility acquisition. This creates opportunities to expand product offerings, leverage manufacturing capabilities, and potentially increase brand presence within China's regulated infant nutrition market.

At the same time, external factors continue to shape the industry's outlook. Consumer spending trends, demographic developments, regulatory requirements, and competitive activity remain important considerations for all infant formula manufacturers operating in China.

Management's emphasis on innovation, manufacturing capability expansion, and supply chain transformation indicates that the company is positioning itself for longer-term participation in the premium nutrition category rather than focusing solely on short-term market conditions.

Conclusion

The a2 Milk Company's receipt of SAMR approval marks an important regulatory achievement that advances its China growth strategy and completes a key requirement linked to the a2 Pokeno facility acquisition. The approval enables the company to utilize two China-label infant formula registrations under the a2™ brand, supporting future product launches and reinforcing its supply chain transformation efforts. Alongside the expected declaration of a $300 million special dividend, the announcement provides investors with greater clarity regarding both strategic execution and capital management initiatives. As new products move toward commercialization later in 2026, market attention is likely to remain focused on how effectively a2 Milk converts this regulatory progress into sustainable business growth within the Chinese infant nutrition market.